Copertina

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety outcomes. Through qualitati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Rasche, Leo (Autore) , Krauth, Maria Theresa (Autore) , Agis, Hermine (Autore) , Renner, Christoph (Autore) , Strassl, Irene (Autore) , Teipel, Raphael (Autore) , Vučinić, Vladan (Autore) , Weisel, Katja (Autore) , Willenbacher, Wolfgang (Autore) , Raab, Marc-Steffen (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 13 May 2026
In: Bone marrow transplantation
Year: 2026, Volume: 61, Fascicolo: 7, Pages: 785-790
ISSN:1476-5365
DOI:10.1038/s41409-026-02905-1
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41409-026-02905-1
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41409-026-02905-1
Testo
Note sull'autore:Leo Rasche, Maria Theresa Krauth, Hermine Agis, Christoph Renner, Irene Strassl, Raphael Teipel, Vladan Vučinić, Katja Weisel, Wolfgang Willenbacher and Marc S. Raab
Descrizione
Riassunto:Use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy to treat relapsed/refractory multiple myeloma is increasing. Studies suggest that effective bridging therapy (BT) prior to anti-BCMA CAR-T therapy can enhance efficacy and safety outcomes. Through qualitative interviews and a consensus workshop, 10 European experts shared their clinical experience regarding optimal BT selection, efficacy, safety and outcomes post-CAR-T, focussing on heavily pretreated patients and emerging BT options, such as bispecific T-cell engagers. Experts agreed that BT should aim to reduce tumour burden and maintain or improve patient performance status, while avoiding treatment-related toxicity that could delay or prevent CAR-T infusion. The balance between treatment duration and achieving an adequate response is important, and patient characteristics are key for BT selection, especially in difficult-to-treat populations. Here, we discuss the unique therapy talquetamab, a GPRC5DxCD3 bispecific antibody, which demonstrates robust efficacy and rapid response rates in clinical trials, and is being considered as a BT option before anti-BCMA CAR-T therapy based on expert experience and real-world data. This consensus, based on clinical experience, aims to provide guidance on BT for healthcare professionals (HCPs) involved in anti-BCMA CAR-T therapy and aid standardisation of care in this rapidly advancing field.
Descrizione del documento:Gesehen am 20.07.2026
Descrizione fisica:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-026-02905-1

Documenti analoghi